Hemera Biosciences is a pioneering biotech company based in Waltham, MA, dedicated to preserving vision through the development of gene therapy. With a focus on age-related macular degeneration (AMD), their groundbreaking one-time treatment, HMR59, is currently undergoing FDA clinical trials to address both the dry and wet forms of the disease.
Driven by a mission to provide effective treatment options for patients with macular degeneration, Hemera Biosciences aims to revolutionize the field of ophthalmology by leveraging gene therapy to combat the overactivity of the complement inflammation cascade. HMR59 works by stimulating retina cells to produce a soluble protein called CD59 sCD59, which effectively blocks the final step of the complement cascade, thereby preserving vision for the lifetime of patients.
Generated from the website